Cargando…
SUN-155 Clinical Experience of SGLT2 Inhibitors in a Hispanic Population: Should We Consider Its Use as Add-On Treatment?
Introduction: 1 in 11 adults have DM globally,(1) and Hispanics have higher complication rates.(2) A study determined that ~$16,750/year are spent by patients in medical related costs, of which ~$9,600 are related to diabetes.(3) Half of Type 2 Diabetes Mellitus (T2DM) patients aren't achieving...
Autores principales: | Zayas, Francisco, Iriarte, R, Vergne, Norma, Hernandez, Luis, Gonzalez, Alex, Mangual, Michelle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553393/ http://dx.doi.org/10.1210/js.2019-SUN-155 |
Ejemplares similares
-
SAT-684 A Deadly Triad: Coexistence of Acute Pancreatitis, Hypertryglyceridemia and Diabetic Ketoacidosis
por: Torres Torres, Marina T, et al.
Publicado: (2020) -
OR22-1 Liraglutide as Add-on to SGLT2 Inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double-Blind, Placebo-Controlled Trial
por: Blonde, Lawrence, et al.
Publicado: (2019) -
SUN-177 House Of Carbs: The Path To Euglycemic Dka In Patients With Diabetes On Sglt2 Inhibitors
por: Islam, Julie, et al.
Publicado: (2019) -
SUN-124 Latent Autoimmune Diabetes of the Adult (LADA): Is It Gestational Diabetes?
por: Cruz Dardiz, Nicolas, et al.
Publicado: (2019) -
Development of Diabetes Type 3 After SARS-COV-2 Pancreatic B Cell Injury
por: Zayas, Francisco Jose, et al.
Publicado: (2021)